AcelRx Pharmaceuticals Inc. (ACRX)

2.90
0.27 10.27
NASDAQ : Health Technology
Prev Close 2.63
Open 2.79
Day Low/High 2.72 / 2.99
52 Wk Low/High 1.65 / 5.05
Volume 7.47M
Avg Volume 1.73M
Exchange NASDAQ
Shares Outstanding 76.39M
Market Cap 195.57M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Stocks Under $10 Weekly Summary

While the overall stock market finished last week essentially unchanged, the portfolio had several outperformers.

First Week Of September 20th Options Trading For AcelRx Pharmaceuticals (ACRX)

First Week Of September 20th Options Trading For AcelRx Pharmaceuticals (ACRX)

Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Stocks Under $10 Weekly Summary

We added one new position and doubled down on another during a very good week for the portfolio.

Stocks Under $10 Weekly Summary

We exited two positions last week as the portfolio and the market started off the year in the green.

AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Data On Sufentanil Sublingual Tablets For Short-term Treatment Of Moderate-to-severe Acute Pain

AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Data On Sufentanil Sublingual Tablets For Short-term Treatment Of Moderate-to-severe Acute Pain

- Over 800 patients from AcelRx studies supporting DSUVIA™ approval were included in the pooled safety analysis

Interesting ACRX Put Options For February 15th

Interesting ACRX Put Options For February 15th

Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new February 15th contracts and identified the following put contract of particular interest.

Adding to This Specialty Pharmaceutical Firm

AcelRx Pharma has really taken it on the chin of late.

AcelRx Pharmaceuticals Added To The NASDAQ Biotechnology Index (NBI)

AcelRx Pharmaceuticals Added To The NASDAQ Biotechnology Index (NBI)

REDWOOD CITY, Calif., Dec.

Stocks Under $10 Weekly Summary

We initiated two new portfolio positions last week.

Stocks Under $10 Weekly Summary

Despite steep declines in the broader market last week, the portfolio had several winners and was helped by our large cash position.

Stocks Under $10 Weekly Summary

We added to two positions last week, as positive action in the market led the Russell 2000 to climb.

AcelRx Pharmaceuticals To Host Analyst And Investor Day On December 11

AcelRx Pharmaceuticals To Host Analyst And Investor Day On December 11

Update on DSUVIA U.S. commercialization strategy and insights from key healthcare professionals

Stocks Under $10 Weekly Summary

Given the market pressures of last week, there was little room to hide as the gut punches continued to hit small-cap and technology stocks.

Stocks Under $10 Weekly Summary

We added to several positions on weakness last week.

Stocks Under $10 Weekly Summary

Despite swimming against the recent tide with small-cap stocks, we have several positions that are more than holding their own.

Portfolio Name's Stock Offering Is Dilutive

We are not adding to our AcelRx position on this weakness, despite believing in the underlying story, until we have more information.

AcelRx Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

AcelRx Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

REDWOOD CITY, Calif., Nov.

AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock

AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock

REDWOOD CITY, Calif., Nov.

Election Impact on the Portfolio

While health care holdings may suffer, cannabis-related holdings should get a boost.

Stocks Under $10 Weekly Summary

We saw a number of our positions rebound along with the market last week.

AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results And Provides Corporate Update

AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results And Provides Corporate Update

- FDA approved DSUVIA™ for use in adults in a certified medically supervised healthcare setting for the management of acute pain

AcelRx Announces FDA Approval Of DSUVIA™

AcelRx Announces FDA Approval Of DSUVIA™

- DSUVIA (sufentanil sublingual tablet 30 mcg) is indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings

Stocks Under $10 Weekly Summary

We re-initiated a position during a volatile week in the market.

Sailing Stormy Seas, Plus Updates on 3 Positions

Here’s when we would consider adding to Aurora Cannabis.

First Week Of June 2019 Options Trading For AcelRx Pharmaceuticals (ACRX)

First Week Of June 2019 Options Trading For AcelRx Pharmaceuticals (ACRX)

Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the June 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: D- (Sell)